EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE)

Ian C Chikanza, Christina Katsiari, Lazaros I Sakkas

Clinical Rheumatology · 2026-07 · 45 (7) · 3853-3864

DOI: 10.1007/s10067-026-08100-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Rheumatology, online erschienen am 07.04.2026. Verfasst von Ian C Chikanza und 2 weiteren Autor:innen. Beteiligte Einrichtung: SJP2 College of Medicine, Catholic University, Harare, Zimbabwe. i.c.chikanza@btinternet.com. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by multiorgan inflammation due to the dysregulation of the immune system. Despite the availability of conventional immunosuppressive therapies, the management of SLE remains challenging due to treatment resistance and significant side effects. Recent advancements in immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy, have shown potential as a novel treatment for autoimmune diseases, including SLE. As of 2025, the treatment landscape for systemic lupus erythematosus (SLE) is undergoing a significant transformation, driven by innovative therapies aiming to provide more effective and potentially curative options for patients. This review provides an overview of the current research on CAR T-cell therapy in SLE, discusses the mechanisms underlying its efficacy, and explores the potential challenges and future directions of this promising therapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsT-Lymphocytes

Stichwörter der Autor:innen

BCMABiodrugBiologicCAR T CellsCD19/BCMACD22CD40LCD9RASLESystemic lupus erythematosus

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • SJP2 College of Medicine, Catholic University, Harare, Zimbabwe. i.c.chikanza@btinternet.com.
  • Pediatrics Department, University of Zimbabwe, Harare, Zimbabwe. i.c.chikanza@btinternet.com.
  • International Arthritis and Hypermobility Centre, Harley Street Clinic, London, UK. i.c.chikanza@btinternet.com.
  • Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
  • School of Health Sciences, University of Thessaly, Larissa, Greece.

Zitieren

APA

Chikanza, I. C., Katsiari, C., & Sakkas, L. I. (2026). Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE). Clinical Rheumatology, 45(7), 3853-3864. https://doi.org/10.1007/s10067-026-08100-3

Vancouver

Chikanza IC, Katsiari C, Sakkas LI. Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE). Clinical Rheumatology. 2026;45(7):3853-3864. doi:10.1007/s10067-026-08100-3

BibTeX
@article{Chikanza2026,
  author = {Chikanza, Ian C and Katsiari, Christina and Sakkas, Lazaros I},
  title = {Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE)},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {7},
  pages = {3853--3864},
  doi = {10.1007/s10067-026-08100-3}
}
Kostenlos starten →